Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carrie E. Robertson is active.

Publication


Featured researches published by Carrie E. Robertson.


Headache | 2013

Expert consensus recommendations for the performance of peripheral nerve blocks for headaches - A narrative review

Andrew Blumenfeld; Avi Ashkenazi; Uri Napchan; Steven D. Bender; Brad C. Klein; Randall Berliner; Jessica Ailani; Jack Schim; Deborah I. Friedman; Larry Charleston; William B. Young; Carrie E. Robertson; David W. Dodick; Stephen D. Silberstein; Matthew S. Robbins

To describe a standardized methodology for the performance of peripheral nerve blocks (PNBs) in the treatment of headache disorders.


Neurology | 2012

Recovery after spinal cord infarcts: Long-term outcome in 115 patients

Carrie E. Robertson; Robert D. Brown; Eelco F. M. Wijdicks; Alejandro A. Rabinstein

Objective: To investigate the long-term outcome of patients with spinal cord infarct (SCI) and identify prognostic predictors. Methods: We reviewed 115 patients with SCI treated between 1990 and 2007. Severity of impairment was defined using the American Spinal Injury Association (ASIA) scoring. Functional outcome endpoints were ambulatory status, need for bladder catheterization, and pain. Results: Mean age was 64 years; 72 (62.6%) patients were men. A total of 45% of infarcts were perioperative (69% aortic surgeries). A total of 68% reached maximal deficit within 1 hour (mean = 5 hours). Impairment at nadir was ASIA A 23%, B 26%, C 14%, and D 37%. A total of 75/93 (81%) patients studied with MRI had cord signal abnormality. At nadir, 81% required wheelchair, 86% required catheterization, and 32% had pain. At last follow-up (mean = 3 years), 23% had died. Among survivors, 42% required a wheelchair, 54% required catheterization, and 29% had pain upon last follow-up. Of 74 patients using a wheelchair at hospital dismissal, 41% were walking by final follow-up. Of 83 patients catheterized at dismissal, 33% were catheter-free at last follow-up. Older age (p < 0.0001), increased severity of impairment at nadir (p = 0.02), and peripheral vascular disease (p = 0.003) were independent risk factors for mortality. Severe impairment (ASIA A/B) at nadir predicted wheelchair use (p < 0.0001) and bladder catheterization (p < 0.0001) at last follow-up. Conclusions: Gradual improvement in not uncommon after spinal cord infarction and it may continue long after hospital dismissal. While severe impairment at nadir is the strongest predictor of poor functional outcome, meaningful recovery is also possible in a substantial minority of these patients.


Headache | 2014

Trigger point injections for headache disorders: expert consensus methodology and narrative review.

Matthew S. Robbins; Deena Kuruvilla; Andrew Blumenfeld; Larry Charleston; Michael R. Sorrell; Carrie E. Robertson; Brian M. Grosberg; Steven D. Bender; Uri Napchan; Avi Ashkenazi

To review the existing literature and describe a standardized methodology by expert consensus for the performance of trigger point injections (TPIs) in the treatment of headache disorders. Despite their widespread use, the efficacy, safety, and methodology of TPIs have not been reviewed specifically for headache disorders by expert consensus.


Headache | 2016

The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache

Matthew S. Robbins; Carrie E. Robertson; Eugene Kaplan; Jessica Ailani; Larry Charleston; Deena Kuruvilla; Andrew Blumenfeld; Randall Berliner; Noah Rosen; Robert Duarte; Jaskiran Vidwan; Rashmi Halker; Nicole Gill; Avi Ashkenazi

The sphenopalatine ganglion (SPG) has attracted the interest of practitioners treating head and face pain for over a century because of its anatomical connections and role in the trigemino‐autonomic reflex. In this review, we discuss the anatomy of the SPG, as well as what is known about its role in the pathophysiology of headache disorders, including cluster headache and migraine. We then address various therapies that target the SPG, including intranasal medication delivery, new SPG blocking catheter devices, neurostimulation, chemical neurolysis, and ablation procedures.


Neuropsychiatric Disease and Treatment | 2012

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine

Carrie E. Robertson; Ivan Garza

OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a novel preventive therapy for migraine headache. The data would support that it may be effective at reducing headache days in patients suffering from chronic migraine (≥15 headache days/month, with eight or more of those migraine headache days). The mechanism by which onabotulinumtoxinA exerts its effects on migraine is not yet understood. It is known to inhibit acetylcholine release at the neuromuscular junction, but this probably does not explain the observed antinociceptive properties noted in preclinical and clinical trials. This review will discuss the known mechanisms of action of botulinum toxin type A, and will review the available randomized, placebo-controlled trials that have looked at its efficacy as a migraine preventative. We also describe the onabotulinumtoxinA injection sites used at our institution.


Seminars in Neurology | 2010

Management of migraine headache in the emergency department.

Carrie E. Robertson; David F. Black; Jerry W. Swanson

Headache is one of the more common reasons for adults to visit an emergency department. Most of these visits are for primary headache disorders, most commonly migraine headache. The authors discuss management options for patients presenting to the emergency department with prolonged, severe, or refractory migraine headaches. Particular attention is given to parenteral treatments and protocols that would not be options as an outpatient. The epidemiology, investigation, and outpatient management of migraine headache are discussed in other articles in this issue.


Journal of Clinical Neuromuscular Disease | 2011

Vasculitic neuropathy associated with minocycline use.

Pariwat Thaisetthawatkul; Robert Sundell; Carrie E. Robertson; Peter James Dyck

Introduction: Minocycline is an antibiotic used for the treatment of acne. It has been associated with several autoimmune syndromes, including drug-induced lupus, autoimmune hepatitis, and vasculitis. Method and Results: We report a case of a 28-year-old previously healthy woman who developed a left sciatic mononeuropathy 2 weeks after starting minocycline for acne. Magnetic resonance imaging studies supported the localization. A biopsy of the left sural nerve revealed acute nerve large arteriole necrotizing vasculitis. Her condition improved after the withdrawal of minocycline and a course of treatment with methylprednisolone. Conclusion: This case provides further evidence that minocycline may induce a nonsystemic necrotizing vasculitis.


Headache | 2016

Procedural Headache Medicine in Neurology Residency Training: A Survey of US Program Directors

Matthew S. Robbins; Carrie E. Robertson; Jessica Ailani; Morris Levin; Deborah I. Friedman; David W. Dodick

To survey neurology residency program directors (PDs) on trainee exposure, supervision, and credentialing in procedures widely utilized in headache medicine.


Cephalalgia | 2013

Triggerless neuralgic otalgia: A case series and systematic literature review

Jonathan H. Smith; Carrie E. Robertson; Ivan Garza; F. Michael Cutrer

Background Isolated neuralgic pain in the deep ear may arise from either nervus intermedius (NIN) or glossopharyngeal (GPN) neuralgias. Current International Headache Society (IHS) International Classification of Headache Disorders, second edition (ICHD-2) criteria for these cranial neuralgias require the presence of a characteristic trigger. Aim The aim of this article is to report cases of triggerless neuralgic otalgia to better understand a subset of patients for whom there may be diagnostic uncertainty. Methods Methods included an observational cohort series and systematic literature review. Results We identified five female patients with a median age at symptom onset of 58 (range: 47 to 73). Our patients generally experienced an excellent clinical response to carbamazepine. Patients were contacted by telephone at a median follow-up duration of seven years (range: four to 32) from symptom onset, at which time carbamazepine-free remissions were reported by five of five (100%) of the patients. A systematic review of the literature on neuralgic otalgia led us to conclude that NIN was most common among young women (age < 50), and GPN across a wider range of ages of either gender. Among surgically validated cases reported in the literature, triggers were frequently absent in NIN, and variably noted in GPN. Conclusions We conclude that the presence of a trigger is not fundamental, and may be impractical, to the diagnosis of neuralgic otalgia, but remains important for specificity between NIN and GPN.


Headache | 2013

Auriculotemporal neuralgia secondary to TMJ synovial cyst: a rare presentation of a rare entity.

Hossein Ansari; Carrie E. Robertson; John I. Lane; Christopher F. Viozzi; Ivan Garza

Synovial cysts of the temporomandibular joint are rare, and to our knowledge, only 14 cases have been reported. The most common presentation is local pain and swelling. We present a case of a synovial cyst presenting with neuralgia in the distribution of the auriculotemporal nerve, initially misdiagnosed as trigeminal neuralgia.

Collaboration


Dive into the Carrie E. Robertson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matthew S. Robbins

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Avi Ashkenazi

Thomas Jefferson University Hospital

View shared research outputs
Top Co-Authors

Avatar

Deborah I. Friedman

University of Texas Southwestern Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge